The phase II JO25567 study revealed that bevacizumab plus erlotinib may prolong PFS in NSCLC patients that presents the activating EGFR gene mutation, compared with erlotinib alone.16 This evidence concerns the gene EGFR and non-small cell lung carcinoma.